Tufts CSDD Free Whitepaper:

Analysis: Decentralized/Hybrid Trials Produce Greater ROI Than Traditional Trials

The data is conclusive, DCTs provide better returns on investment than traditional trials. 

In fact, new analysis by Tufts CSDD shows DCTs can provide up to:

  • 13x ROI in Phase 3 trials
  • 5x ROI in Phase 2 trials

Through reductions in clinical trial cycle time, screen failure reductions, and more.

Learn more with your free copy of the analysis. 

Who is Tufts CSDD?

Tufts CSDD is an independent, academic, non-profit research center at Tufts University in Boston. Founded in 1976, the university is, dedicated to researching drug development.

Heading

Heading

Heading

Save the Date!
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
Learn why Tuft's research will transform your trials